Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired therapies to address a range of mental health and neurological disorders. The company applies traditional drug development techniques to molecules derived from psychedelic compounds, with an emphasis on safety, efficacy and scalable manufacturing. Its research and development activities span small-molecule analogues, novel formulations and digital therapeutics designed to enhance or support pharmacological interventions.
The company’s lead development programs include MM-120, an investigational low-dose LSD formulation intended for treatment of anxiety; MM-310, an ibogaine-derived non-hallucinogenic compound targeting opioid withdrawal and addiction; and MM-402, a proprietary 5-MeO-DMT receptor agonist for mood and stress-related indications. These programs are advancing through various stages of clinical and preclinical investigation, with MindMed collaborating with academic centers and contract research organizations to conduct randomized controlled trials.
Founded in 2019 and headquartered in New York with additional research operations in Europe, MindMed went public on the Nasdaq exchange in 2021. The company is led by CEO JR Rahn, who brings experience from the biotechnology and healthcare investment sectors, alongside a management team with backgrounds in neurology, psychiatry and pharmaceutical development. MindMed maintains strategic partnerships and licensing arrangements to access synthetic routes for psychedelic compounds and to explore complementary digital health platforms.
MindMed’s goal is to transform the treatment landscape for psychiatric and neurological conditions by combining rigorous clinical science with innovative therapeutic modalities. While its programs remain investigational, the company has attracted attention for its disciplined approach to a field that blends traditional drug discovery with novel psychopharmacology.
AI Generated. May Contain Errors.
